Alembic Pharmaceuticals shares surged nearly 5% today – as of 9:35 am the shares were trading 4.33% higher at
₹1,086.95 on NSE.
Alembic Pharmaceuticals faced a setback as the United States Food and Drug Administration (US FDA) issued a Form 483 with five procedural observations after inspecting its Solid Oral Formulation Facility (F-4) in Jarod, Gujarat. The inspection, which was a scheduled Good Manufacturing Practice (GMP) audit, took place from November 14 to November 22, 2024.
The company announced that it is committed to addressing the procedural observations highlighted by the US FDA and will provide a comprehensive response within the stipulated timeframe. Alembic Pharmaceuticals reiterated its dedication to maintaining the highest quality standards and compliance at all times.
